DuraStat, LLC, an Austin, TX-based precision surgical tissue closure company, closed an over $5M Series B funding round.
The backers were not disclosed.
The company intends to use the funds to proliferate its flagship dural repair product to every spine facility and to accelerate upcoming product launches.
Led by Adam Azzara, CEO, DuraStat is a medical device company focused on precision suturing, which enables fast, atraumatic tissue approximation by eliminating wrist rotation. DuraStat was invented by Greg Anderson, MD and Mark Kurd, MD (Thomas Jefferson University and Rothman Institute) and developed for global scalability with Kevin Foley, MD (Semmes-Murphey) and Alex Lukianov.
The company plans to leverage its expertise and intellectual property portfolio to launch an additional spine product by late 2022 with more coming to market throughout 2023. Applications beyond spine will soon follow.
FinSMEs
29/04/2022